Recruitment

Recruitment Status
Terminated

Exclusion Criterias

Those allergic to compounds similar to the study medication.
Diagnosis of other primary/secondary headache disorder.
Those who have had any prior exposure to any botulinum toxin serotype.
...
Those allergic to compounds similar to the study medication.
Diagnosis of other primary/secondary headache disorder.
Those who have had any prior exposure to any botulinum toxin serotype.
Subjects who abuse drugs, including headache treatments and alcohol (DSM IV criteria).
Those who are pregnant or breastfeeding, or who do not use adequate contraceptive methods.
Those with relevant physical or psychological illness, particularly conditions that might put them at risk if exposed to OnabotulinumtoxinA (myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or any other neuromuscular disease).
Psychiatric disorders that could interfere with study participation.

Summary

Conditions
New Daily Persistent Headache
Type
Interventional
Phase
Phase 2
Design
  • Allocation: N/A
  • Intervention Model: Single Group Assignment
  • Masking: None (Open Label)
  • Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Exclusion Criterias

Those allergic to compounds similar to the study medication.
Diagnosis of other primary/secondary headache disorder.
Those who have had any prior exposure to any botulinum toxin serotype.
...
Those allergic to compounds similar to the study medication.
Diagnosis of other primary/secondary headache disorder.
Those who have had any prior exposure to any botulinum toxin serotype.
Subjects who abuse drugs, including headache treatments and alcohol (DSM IV criteria).
Those who are pregnant or breastfeeding, or who do not use adequate contraceptive methods.
Those with relevant physical or psychological illness, particularly conditions that might put them at risk if exposed to OnabotulinumtoxinA (myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or any other neuromuscular disease).
Psychiatric disorders that could interfere with study participation.

Locations

New York, New York, 10019
New York, New York, 10019

Tracking Information

NCT #
NCT01920945
Collaborators
Allergan
Investigators
Not Provided